Quarterly Result: Aarti Drugs Ltd.
Bhagyashree Vivarekar / 09 Nov 2016
Aarti Drugs Ltd ended at Rs. 629.9, up by 5.2 points or 0.83% from its earlier closing of Rs. 624.7 on the BSE. The company's net profit has jumped 40.5% yoy to Rs 22 cr, and this was majorly owing to to 18.6% dip in finance costs.
Technical View:
Aarti Drugs Ltd ended at Rs. 629.9, up by 5.2 points or 0.83% from its earlier closing of Rs. 624.7 on the BSE.
The scrip touched a high and low of Rs. 650 and Rs. 529.1 respectively, after opening at 602.2. Altogether 28774(NSE+BSE) shares were traded on the counter; and the stock is trading below its 50 DMA.
Consolidated Results Q2FY17:
Aarti Drugs Ltd., has reported its Q2FY17 numbers in-conjunction with Bloomberg estimates. Revenue stands at Rs 316 cr compared to estimate of Rs 314 Cr while net profit was equivalent to estimated 22 cr.
The quarter's revenue has soared 15.7% yoy to Rs 316 cr.
Aarti Drugs' reported EBITDA has climbed 20.2% yoy to Rs 51 cr while EBITDA margins have improved by 60 bps yoy to 16.2%. This was anchored by operational efficiency.
The company's net profit has jumped 40.5% yoy to Rs 22 cr, and this was majorly owing to to 18.6% dip in finance costs.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.